NCT02516527View on ClinicalTrials.gov

A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 16, 2015

Primary Completion Date

September 20, 2018

Study Completion Date

September 20, 2018

Conditions
Melanoma
Interventions
DRUG

Ipilimumab

Trial Locations (1)

510060

Local Institution, Guangzhou

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02516527 - A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors | Biotech Hunter | Biotech Hunter